Dear Omer,
I know that people at Pharmos, other Israeli medical people and even some SI posters seem to have thought very little about the Washington Post brief on the American doctor/NIMH announcement of very early clinical work in cannabinoids. "We're much more advanced than they are," is the common retort.
Well, from a shareholder perspective, how much does matter if no one knows outside the Israeli medical field? On Wall Street, valuations follow the amount of interest generated for a given company and that usually means people must hear about the company to invest/believe in it. In this respect, because of our lack of Street coverage, PARS shareholders are at a disadvantage.
Here's more coverage for the NIMH story. Rather than dismiss it, Pharmos should do some outreach to this publication. NewScientist editors are, after all, knowledgeable about the British debate on allowing more research into cannabis derivatives. And they are devoting a lot of space in their publication to the topic. Moreover, subscribers (potential shareholders?) are writing in too.
I'll subscribe to this publication just to write a letter to the editor. Hope other people might too. Hope, especially, that Pharmos will call/e-mail these folks and announce their presence. That's not hype. That's just common sense PR. I was able to buy shares below the $ 2 1/2 mark this week, more than a dime cheaper than Haim Aviv did recently.
We need a more pro-active approach to PR!
newscientist.com
Shalom,
Ariella |
